Background: Epidermal growth factor receptor and anaplastic lymphoma kinase play key roles in tumorigenesis and disease progression. Currently, targeted therapy is a better approach for cancer therapy compared with traditional chemotherapy. EGFR-based/ALK-based target therapies are key targets for drug development in cancer therapy.

Objective: The objective of this study was to show a recent trend in research and development of EGFR-based/ALK-based targets and to better understand the Intellectual Property surrounding EGFR-based and ALK-based targets.

Methods: EGFR-based and ALK-based targets were analyzed by comprehensive US patent analysis. US patents of EGFR-based/ALK-based targets were analyzed from September 2001 to September 2020.

Results: The results indicated that the key technologies and methods of EGFR-based/ALK-based targets were developed by large global pharmaceutical companies or American companies/universities. Small molecular inhibitors showed a higher percentage in the number of patents of EGFRbased targets. In addition, the present study also showed recent small molecular targeted drugs approved by FDA.

Conclusion: Global large pharmaceutical companies and American companies/universities have obvious advantages in the research and development of targeted drugs. EGFR-based target was still an attractive target for research and drug development in the past 10 years. Also, large global pharmaceutical companies prefer to complete key technology research and development by independent innovation instead of collaboration.

背景：表皮生长因子受体和间变性淋巴瘤激酶在肿瘤发生和疾病进展中起关键作用。目前，与传统化疗相比，靶向治疗是一种更好的癌症治疗方法。基于EGFR/ALK的靶向治疗是癌症治疗药物开发的关键靶点。

目的：本研究的目的是展示基于 EGFR/基于 ALK 的靶标研究和开发的最新趋势，并更好地了解基于 EGFR 和基于 ALK 的靶标的知识产权。

方法：通过综合美国专利分析分析基于 EGFR 和基于 ALK 的靶标。从 2001 年 9 月到 2020 年 9 月，对基于 EGFR/基于 ALK 的靶标的美国专利进行了分析。

结果：结果表明，基于EGFR/ALK靶点的关键技术和方法由全球大型制药公司或美国公司/大学开发。小分子抑制剂在基于EGFR的靶点专利数量中显示出更高的百分比。此外，本研究还展示了最近获得 FDA 批准的小分子靶向药物。

结论：全球大型制药公司和美国公司/大学在靶向药物研发方面具有明显优势。在过去的 10 年中，基于 EGFR 的靶点仍然是研究和药物开发的一个有吸引力的靶点。此外，全球大型制药企业更愿意通过自主创新而非合作完成关键技术研发。